An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune <a target=_blank h ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

On December 17, 2024, the Competition Tribunal (the Tribunal) issued reasons for its decision to dismiss an application for leave to bring a ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Accord Healthcare Limited (Accord) announces that the European Commission (EC) has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar of Stelara® (ustekinumab), ...

Celltrion Inc.'s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company ...